11/8/2024 - In this comprehensive discussion, four prominent neuromuscular experts—Drs. Bhaskar Roy, Jeff Allen, Diana Castro, and Luis Querol—explore recent developments in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The conversation centers on the new European Academy of Neurology and Peripheral Nerve Society guidelines, highlighting significant changes in diagnostic criteria and disease classification. The experts discuss the challenges of diagnosing CIDP, particularly in pediatric cases and variant forms, while emphasizing the importance of proper electrodiagnostic testing and the role of supportive criteria like CSF studies and MRI. They delve into the emerging field of autoimmune neuropathies and the significance of specific antibody testing. The podcast concludes with a discussion of treatment options, including traditional approaches (IVIG, corticosteroids, plasmapheresis) and newer therapies such as FcRn inhibitors and complement-targeting drugs, while also addressing the controversial role of rituximab in CIDP treatment. Throughout the discussion, the experts stress the importance of regular diagnostic reassessment and the need for more personalized treatment approaches based on patient profiles. 34 min

10/15/2024-  Dr. Chilvana Patel interviews Dr. Michelle Mauermann and Dr. Eli Naddaf on the important topic of paraprotenemic neuropathies. They offer valuable insights into a step-by-step approach to understanding the clinical features, conducting electrodiagnostic studies, and managing these conditions. 25 minutes

9/30/2024-  Despite its recognition for nearly 40 years, anti-MAG neuropathy continues to have limited therapeutic options. The emergence of bruton tyrosine kinase inhibition as a new therapeutic pathway appears promising. In this interview, Dr. Amro Stino interviews Dr. Chiara Briani on her 2023 paper exploring the prevalence of the MYD 88 mutation among patients with anti-MAG neuropathy. This is discussed within the broader context of disease presentation, current treatment landscape, and future drug development. - 29 minutes